OverviewSuggest Edit

AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. Its product candidates, DSUVIA (also known as DZUVEO) and ZALVISO, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings.

TypePublic
Founded2005
HQRedwood City, US
Websiteacelrx.com

Latest Updates

Employees (est.) (Dec 2019)99(+4%)
Revenue (FY, 2019)$2.3 M(+7%)
Share Price (Nov 2020)$1.5
Cybersecurity ratingBMore

Key People/Management at AcelRx Pharmaceuticals

Vincent J. Angotti

Vincent J. Angotti

Chief Executive Officer, Director
Pamela P. Palmer

Pamela P. Palmer

Chief Medical Officer and Co-Founder, Director
Raffi Asadorian

Raffi Asadorian

Chief Financial Officer
Larry G. Hamel

Larry G. Hamel

Chief Development Officer
Badri Dasu

Badri Dasu

Chief Engineering Officer
Adrian Adams

Adrian Adams

Chairman of the Board
Show more

AcelRx Pharmaceuticals Office Locations

AcelRx Pharmaceuticals has an office in Redwood City
Redwood City, US (HQ)
351 Galveston Dr
Show all (1)

AcelRx Pharmaceuticals Financials and Metrics

AcelRx Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
AcelRx Pharmaceuticals's revenue was reported to be $2.29 m in FY, 2019 which is a 6.4% increase from the previous period.
USD

Revenue (Q3, 2020)

1.4m

Gross profit (Q3, 2020)

(483.0k)

Gross profit margin (Q3, 2020), %

(35.3%)

Net income (Q3, 2020)

(8.9m)

EBIT (Q3, 2020)

(9.0m)

Market capitalization (20-Nov-2020)

138.4m

Closing stock price (20-Nov-2020)

1.5

Cash (30-Sept-2020)

20.0m

EV

146.1m
AcelRx Pharmaceuticals's current market capitalization is $138.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

8.0m2.2m2.3m

Revenue growth, %

(54%)(73%)6%

Cost of goods sold

10.7m4.0m6.8m

Gross profit

(2.7m)(1.8m)(4.5m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

52.9m88.0m14.7m

Accounts Receivable

1.5m49.0k432.0k

Prepaid Expenses

455.0k1.0m1.7m

Inventories

956.0k854.0k3.3m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(51.5m)(47.1m)(53.2m)

Depreciation and Amortization

1.7m575.0k1.7m

Inventories

920.0k102.0k(3.4m)

Accounts Payable

309.0k458.0k(19.0k)
USDQ1, 2017

Financial Leverage

-4.5 x
Show all financial metrics

AcelRx Pharmaceuticals Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Patents (Foreign)

24 27 27 27

Patents (US)

20 22 22 25
Show all operating metrics

AcelRx Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Tetraphase Pharmaceuticals, IncMarch 16, 2020
ARPI LLC

AcelRx Pharmaceuticals Revenue Breakdown

Embed Graph

AcelRx Pharmaceuticals revenue breakdown by business segment: 39.0% from Contract and Other and 61.0% from Collaboration Agreement

AcelRx Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

AcelRx Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

AcelRx Pharmaceuticals Online and Social Media Presence

Embed Graph

AcelRx Pharmaceuticals News and Updates

AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results

REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter...

Thinking about buying stock in Just Energy, Extreme Networks, Aurora Cannabis, AcelRx Pharmaceuticals, or Rigel Pharmaceuticals?

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JE, EXTR, ACB, ACRX, and RIGL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

AcelRx Pharmaceuticals Announces Publication of Clinical Data on Reduced Opioid Use and Reduced Time in the Postanesthesia Care Unit (PACU) Following Preoperative Administration of DSUVIA®

REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a study...

AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase

REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does not...
Show more

AcelRx Pharmaceuticals Frequently Asked Questions

  • When was AcelRx Pharmaceuticals founded?

    AcelRx Pharmaceuticals was founded in 2005.

  • Who are AcelRx Pharmaceuticals key executives?

    AcelRx Pharmaceuticals's key executives are Vincent J. Angotti, Pamela P. Palmer and Raffi Asadorian.

  • How many employees does AcelRx Pharmaceuticals have?

    AcelRx Pharmaceuticals has 99 employees.

  • What is AcelRx Pharmaceuticals revenue?

    Latest AcelRx Pharmaceuticals annual revenue is $2.3 m.

  • What is AcelRx Pharmaceuticals revenue per employee?

    Latest AcelRx Pharmaceuticals revenue per employee is $23.1 k.

  • Who are AcelRx Pharmaceuticals competitors?

    Competitors of AcelRx Pharmaceuticals include Cidara Therapeutics, Reata Pharmaceuticals and JanOne.

  • Where is AcelRx Pharmaceuticals headquarters?

    AcelRx Pharmaceuticals headquarters is located at 351 Galveston Dr, Redwood City.

  • Where are AcelRx Pharmaceuticals offices?

    AcelRx Pharmaceuticals has an office in Redwood City.

  • How many offices does AcelRx Pharmaceuticals have?

    AcelRx Pharmaceuticals has 1 office.